BioRestorative Therapies, Inc.

BRTX

CIK 0001505497 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$20K
↓-54.7% -$24Kvs FY2024 (Q4)
Gross Profit
$18K
↓-55.0% -$22Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
19/100
  • Profitability
    0ROIC -278.2% (10% = solid, 20%+ = moat)
  • Liquidity
    17Current Ratio 0.84 (above 1.5 = solid)
  • Leverage
    99D/E 0.01 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.04x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -54.7% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -31432.3% · trend -12087.2pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$116K
investment in PP&E
Stock buybacks (TTM)
$0
share count reduction
Stock-based comp (TTM)
$3M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$4M
everything owned
Total liabilities
$4M
everything owed
Stockholders' equity
$357K
shareholder claim
Net debt
$-1M
Net cash position ($1M)

Recent performance · 63 quarters

Revenue↓-54.7% -$24K
$20K
Net Income↓-178.4% -$2M
$-3M
Free Cash Flow↓-540.7% -$67K
$-80K
Operating Margin↓-30453.3pts
-31432.3%

Drill down